MedPath

Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain)

Not Applicable
Completed
Conditions
Alzheimer Disease
Registration Number
NCT06275243
Lead Sponsor
Universidad de León
Brief Summary

The general objective of this randomized and longitudinal clinical study was to estimate the frequencies of ApoE variants both in the user population of the "Messengers of Peace" Residences and the "Associations of Relatives of Alzheimer's Patients" in Castile y Leon, since, due to its geographical location at the crossroads, it has received multiple genetic contributions from both northern Europe, the Mediterranean area and northern Africa.

The main questions it aims to answer are:

* What are the allelic frequencies of ApoE variants in the population of individuals with Alzheimer's disease in Castile and Leon?

* Is there a correlation between the ApoE4 variant and the lipid profile in the blood of individuals with Alzheimer's disease in this region?

Detailed Description

In the context of Alzheimer disease research, it is widely recognized that the ApoE gene plays a fundamental role in the genetic predisposition of this disease. With three major alleles: ApoE2, ApoE3, and ApoE4, genetic variability in the ApoE gene has been the subject of extensive attention in previous research and its association with increased risk of Alzheimer's disease has remained consistent. Within this framework, three hypotheses are proposed focused on understanding the specific influence of ApoE on Alzheimer's disease and exploring the possible underlying mechanisms.

Within this framework, three hypotheses are proposed focused on understanding the specific influence of ApoE on Alzheimer disease and exploring the possible underlying mechanisms:

1. - Research hypotheses: The genetic variant ApoE4/4 is significantly related to a higher risk of developing Alzheimer's disease compared to individuals who do not carry this genotype.

2. - Research hypotheses: The ApoE2/2 genetic variant is associated with a lower risk of developing Alzheimer's disease compared to other genotypes.

3. - Research hypotheses: People who carry the ApoE4 isoform have elevated levels of total cholesterol and LDL-cholesterol.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
511
Inclusion Criteria
  • Be between 60 and 90 years old.
  • Subjects with a diagnosis of AD in the case group.
  • Subjects free of AD diagnosis in the control group.
  • Subjects who voluntarily and consented to participate free of charge.
  • Have completed the written consent
Exclusion Criteria
  • Subjects who, at the time of sample collection, had behavioral or other alterations that made the sample collection procedure impossible.
  • Subjects who, at the time of sample collection, presented oral alterations incompatible with the technique.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Distribution of ApoE variants in the Alzheimer's disease population diagnosed in Castile and Leon.9 months

The saliva samples will be processed to purify and extract DNA. Subsequently, a PCR amplification will be performed to check the ApoE alleles and genotypes.

Secondary Outcome Measures
NameTimeMethod
ApoE genotypes and cholesterol levels in the Alzheimer's disease population diagnosed in Castile and Leon.9 months

To assess the presence of significant differences in the mean cholesterol values across different genotypes, an analysis of variance (ANOVA) test will be applied.

Cardiovascular factors in individuals with Alzheimer's disease and healthy subjects.9 months

We will analyze whether there are significant differences between individuals with Alzheimer's disease and healthy subjects in terms of cardiovascular risk factors (Diabetes mellitus, cardiac pathology, hypercholesterolemia and high blood pressure) using the z-test for difference in proportions.

Trial Locations

Locations (1)

University of León

🇪🇸

León, Spain

University of León
🇪🇸León, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.